Parkinson Progression Marker Initiative Online (PPMI Online)

Parkinson Disease Clinical Trial

Official title:

Parkinson's Progression Markers Initiative Online Study (PPMI Online)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05065060
• Other study ID #: PPMI-007
• Status: Recruiting
• Start date: July 28, 2021
• Est. completion date: December 2041

Study information

• Verified date: April 2023
• Source: Michael J. Fox Foundation for Parkinson's Research
• Contact: University of California, San Francisco
• Phone: 877-525-7764
• Email: info[@]ppmionline.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Description:

PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical [NCT04477785], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500000
• Est. completion date: December 2041
• Est. primary completion date: December 2041
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Parkinson Disease (PD) Participants:
• Male or female age 18 years or older.
• Has received a diagnosis of Parkinson's disease

Participants without PD:

• Male or female age 18 years or older.
• Has not received a diagnosis of Parkinson's disease

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Other:
• Observation
Observation

Locations

Country	Name	City	State
United States	UCSF Movement Disorders and Neuromodulation Center (MDNC)	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Michael J. Fox Foundation for Parkinson's Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Unified Parkinson's Disease Rating Scale Ib & II	Evaluates self-reported motor and nonmotor Parkinson's disease symptoms	Baseline to 240 months